SE9700885D0 - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation

Info

Publication number
SE9700885D0
SE9700885D0 SE9700885A SE9700885A SE9700885D0 SE 9700885 D0 SE9700885 D0 SE 9700885D0 SE 9700885 A SE9700885 A SE 9700885A SE 9700885 A SE9700885 A SE 9700885A SE 9700885 D0 SE9700885 D0 SE 9700885D0
Authority
SE
Sweden
Prior art keywords
dosage form
pharmaceutical formulation
new pharmaceutical
unit tableted
formulations
Prior art date
Application number
SE9700885A
Other languages
Swedish (sv)
Inventor
Stig Wendsjoe
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9700885A priority Critical patent/SE9700885D0/en
Publication of SE9700885D0 publication Critical patent/SE9700885D0/en
Priority to JP53949898A priority patent/JP2001515489A/en
Priority to EP98909899A priority patent/EP0981335A1/en
Priority to AU64268/98A priority patent/AU6426898A/en
Priority to PCT/SE1998/000356 priority patent/WO1998040054A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An enteric coated oral dosage form comprising sodium amoxycillin, wherein the dosage form is a single unit tableted dosage form or a multiple unit tableted dosage form is claimed. Processes for the manufacture of the dosage forms as well as the formulations, use in the treatment of Helicobacter pylori infections are claimed.
SE9700885A 1997-03-12 1997-03-12 New pharmaceutical formulation SE9700885D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE9700885A SE9700885D0 (en) 1997-03-12 1997-03-12 New pharmaceutical formulation
JP53949898A JP2001515489A (en) 1997-03-12 1998-02-27 Enteric coated oral dosage form consisting of amoxicillin sodium
EP98909899A EP0981335A1 (en) 1997-03-12 1998-02-27 An enteric coated oral dosage form comprising sodium amoxycillin
AU64268/98A AU6426898A (en) 1997-03-12 1998-02-27 An enteric coated oral dosage form comprising sodium amoxycillin
PCT/SE1998/000356 WO1998040054A1 (en) 1997-03-12 1998-02-27 An enteric coated oral dosage form comprising sodium amoxycillin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9700885A SE9700885D0 (en) 1997-03-12 1997-03-12 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE9700885D0 true SE9700885D0 (en) 1997-03-12

Family

ID=20406120

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9700885A SE9700885D0 (en) 1997-03-12 1997-03-12 New pharmaceutical formulation

Country Status (5)

Country Link
EP (1) EP0981335A1 (en)
JP (1) JP2001515489A (en)
AU (1) AU6426898A (en)
SE (1) SE9700885D0 (en)
WO (1) WO1998040054A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69617036T2 (en) 1995-09-07 2002-07-11 Smithkline Beecham Corp., King Of Prussia USE OF A PEDIATRIC PHARMACEUTICAL FORMULATION CONTAINING AMOXICILLIN AND CLAVULANATE
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
EA004310B1 (en) * 1999-04-13 2004-02-26 Бичам Фармасьютикалз (Пте) Лимитед Novel method of treatment
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
GB0031267D0 (en) * 2000-12-21 2001-01-31 Smithkline Beecham Plc Novel compositions
SE0101379D0 (en) * 2001-04-18 2001-04-18 Diabact Ab Composition that inhibits gastric acid secretion
ES2198195B1 (en) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. COMPRESSED ORAL PHARMACEUTICAL DOSAGE FORM, WITH ENTERIC COATING, CONTAINING A LABIL BENCIMIDAZOL COMPOUND IN THE MIDDLE ACID.
SE0203065D0 (en) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
RU2006132127A (en) * 2006-09-06 2008-03-20 Государственное Учреждение Научный Центр Здоровьядетей Российской Академии Медицинских Наук (Гу Нцзд Рамн) (Ru) APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR
CN109893516A (en) 2013-02-13 2019-06-18 红山生物医药有限公司 For treating the pharmaceutical composition of helicobacter pylori
CN107405338A (en) * 2015-01-09 2017-11-28 加州大学评议会 For treating the composition and method of alimentary infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201930D0 (en) * 1992-06-24 1992-06-24 Astra Ab GASTRIC ANTIBACTERIAL TREATMENT
GB9405856D0 (en) * 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole

Also Published As

Publication number Publication date
JP2001515489A (en) 2001-09-18
AU6426898A (en) 1998-09-29
WO1998040054A1 (en) 1998-09-17
EP0981335A1 (en) 2000-03-01

Similar Documents

Publication Publication Date Title
SE9700885D0 (en) New pharmaceutical formulation
MX9604354A (en) New oral pharmaceutical dosage form.
ID27504A (en) NEW ORAL FORMULATION
EE200000329A (en) Oral Form For Acid-Unstable Active Ingredients, Method Of Preparation And Use Of A Unit Of Acid-Unstable Active Ingredient
BR0107565A (en) Replaced benzimidazole dosage forms and methods of use
CL2009001279A1 (en) Nociceptin derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of pain (sol. divisional 2103-03).
CY1107675T1 (en) TRAMADOLIS MEDICINES
IS4146A (en) A pharmaceutical preparation for oral administration of proton pump blockers
NO20012222L (en) Pharmaceutical formulation including omeprazole
HUP0201877A2 (en) Fast-dispersing dosage forms containing fish gelatin
HUP0004383A2 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
ATE211907T1 (en) OSMOTIC DRUG RELEASE SYSTEM
SE9504661D0 (en) New compounds
HUP0104318A2 (en) Controlled-release pharmaceutical formulations containing acgmp pde-5 inhibitor
DE60019334D1 (en) ANTIVIRAL ARZNEI
HUP0301349A2 (en) Formulations for il-11
NO20034863L (en) Deuterated 3-piperidinopropiophenone as well as drugs containing these compounds
DE50005529D1 (en) ORAL PHARMACEUTICAL FORMS FOR ADMINISTRATING A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
HUP0104647A2 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
ID28510A (en) NEW ORAL FORMULATION FOR AGONISTS OR 5-HT4 ANTAGONISTS
DE60102590T2 (en) PHARMACEUTICAL FORMS FOR THE TREATMENT OF ORAL MYCOSES
RS50298B (en) Directly compressibile matrix for controlled release of single daily doses of clarithromycin
HUP9801924A2 (en) Pharmaceutical composition containing sodium-hydrogen-exchange-inhibitors and cardiovascular active agents
ATE360428T1 (en) ANALGESIC MEDICINAL PRODUCT
IS6532A (en) Dosage formulation for oral administration of ziprofloxacin once daily